A preclinical study showed that injection of a DNA vaccine encoding full-length prostatic acid phosphatase (PAP) antigen elicited an antigen-specific CD8+ T cells in rodents [18], led to a phase I/IIa trial with a DNA vaccine encoding human PAP in patients with stage D0 prostate cancer with the goal to elicit a sustainable immune response, able to eradicate a tumor or at least, restrain its growth [52]. Here, ACP3 is linked to neoplasm.